Merck/Schering Zetia Early Use Is In High-Risk Patients; New Rx Share At 5%
Executive Summary
Schering-Plough is seeing most of the early use of Zetia in either high-risk or statin-intolerant patients, Global Pharmaceuticals President Carrie Cox told investors during a quarterly earnings call Oct. 22
You may also be interested in...
Pegasys Market Position Secure, Roche Says; Dismisses PEG-Intron Data
Roche expects to have firmly established its leadership position in the hepatitis C market with Pegasys by the time Schering-Plough publishes the results from its ongoing head-to-head study versus PEG-Intron
Pegasys Market Position Secure, Roche Says; Dismisses PEG-Intron Data
Roche expects to have firmly established its leadership position in the hepatitis C market with Pegasys by the time Schering-Plough publishes the results from its ongoing head-to-head study versus PEG-Intron
Schering Sales Force Recruitment Is 80% Complete; Morale Remains High
Recruitment for Schering-Plough's sales force expansion is 80% complete, Global Pharmaceutical President Carrie Cox told investors during a year-end conference call Jan. 26